Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

A Food and Drug Administration (FDA) advisory panel overwhelmingly rejected MDMA-assisted therapy for treating post-traumatic ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Advocates are pushing for approval of psychedelic-assisted therapy from the FDA, seeking a means of therapy without fear of ...

A Boulder-based therapist characterized the decision as an enormous setback for those seeking treatment for PTSD.

Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...

The post A Setback for MDMA-Assisted Psychotherapy appeared first on Reason.com. Autoblog chats to a hardcore Mustang fan and ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...

Lykos Therapeutics CEO and founder Amy Emerson is stepping down, with Chief Operating Officer Michael Mullette taking over ...

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...